Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Preannounces Q4 Revenues of $33.4M

NEW YORK (GenomeWeb) – Fluidigm said after the close of the market on Tuesday that its revenue for the fourth quarter of 2014 is expected to be approximately $33.4 million.

On average, analysts were expecting Q4 revenues of $33.3 million for the South San Francisco, Calif.-based life science analytical and preparatory systems firm.

Organic revenue for Q4 — excluding revenue attributable to its acquisition of DVS Sciences in January 2014 — is expected to be approximately $25.2 million, which would be a 21 percent increase over the $20.9 million in revenues recorded by the company in Q4 2013.

Meantime, Fluidigm said that total revenue for full-year 2014 is expected to be $116.4 million, while organic revenue, less DVS Sciences' contribution, is expected to be $95.9 million.

Fluidigm projects total revenue of between $142 million and $149 million for full-year 2015. These projections incorporate an estimated negative currency-related impact of 3 percent to 4 percent at the midpoint of the range.

"We achieved strong sequential growth within our CyTOF single-cell proteomics product line both in terms of revenue and bookings," Fluidigm CEO Gajus Worthington said in a statement. "Our full-year results are at the high end of our previously stated guidance, despite a currency headwind in the quarter. As in the third quarter, we realized commercial synergy between single-cell genomics and proteomics at a customer and sales representative level."

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.